Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

hen used together," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Through our portfolio of high blood pressure medications, Novartis is committed to providing physicians with a wide range of tools to help patients lower their blood pressure."

About Tekturna

Tekturna received FDA approval in March 2007 for the treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied. Tekturna was developed in collaboration with Speedel.

In clinical trials, the approved doses of Tekturna were generally well tolerated and the most common side effect experienced by more patients taking Tekturna than patients taking a sugar pill was diarrhea. Other less common reactions to Tekturna include cough and rash.

Angioedema has been rarely reported in patients taking Tekturna.

About Diovan

Novartis remains at the forefront of cardiovascular medicine through development of innovative products like DIOVAN, the most-prescribed member of the ARB class (angiotensin receptor blocker) in the world today. DIOVAN is available for the treatment of high blood pressure in more than 100 countries, for the treatment of heart attack survivors in more than 70 countries and in more than 90 countries for the treatment of people with heart failure.

DIOVAN is contraindicated in patients who are hypersensitive to any component of this product.

Volume and or salt depletion should be corrected in patients prior to administering DIOVAN or symptomatic hypotension may occur.

Care should be exercised with dosing of DIOVAN in patients with severe renal impairment. As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be observed in susceptible individuals (e.g. patients with renal artery stenosis or severe heart failure).

No significant differences b
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/28/2014)... PLYMOUTH MEETING, Pa. , Aug. 28, 2014 ... surgical community, patients, and media, both for the ... to patient safety. The quick deployment of surgical ... new technology are prompting facilities to evaluate their ... for the entire surgical team.    ...
(Date:8/28/2014)... 2014 Amgen (NASDAQ: AMGN ) ... (BLA) to the U.S. Food and Drug Administration (FDA) ... cholesterol. Evolocumab is an investigational fully human monoclonal antibody ... protein that reduces the liver,s ability to remove low-density ... 1 ­ The BLA ...
(Date:8/28/2014)... ALISO VIEJO , Kalifornien, 28. ... Inc., hat heute den Start der ... Investigational Device Exemption, Forschungsausnahmegenehmigung) zur Beurteilung ... Systems zur Embolisation von Aneurysmen („WEB") ... University of Tennessee, Department of Neurosurgery/Semmes-Murphey ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
(Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
(Date:8/28/2014)... 70 and over who identify themselves as ,old, feel ... perceive they have lower value than younger age groups. ... Kent, titled ,Being old and ill, across different countries: ... used data from the European Social Survey. Respondents, who ... self-rate their health., The researchers found that those living ...
(Date:8/28/2014)... August 28, 2014 Vaccine market - ... great interest among other healthcare industry sectors and sub-circles ... demand in vaccine with respect to evolving and spreading ... due to an improved understanding for a well-balanced life ... States. It has led to new opportunities for manufacturing ...
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Steven Reinberg HealthDay ... Treating pre-cancerous skin spots with a type of light therapy ... the lesions with liquid nitrogen, a new study suggests. ... the scalp and face of people with fair complexions who,ve ... of prior research found that people who underwent the light ...
Breaking Medicine News(10 mins):Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 3
... ... Hearing Institute (BHI) is urging families across America to make 2010 the year ... in response to new data that underscores the influence family members have in ... of nearly 47,000 households, more than half (51%) of new first-time owners of ...
... ... home top honors in American Spa Magazine,s 2009 Professional,s Choice Award in the Favorite ... ... 8, 2009 -- Oakworks® Inc., the premier U.S. manufacturer of wellness, spa, massage and ...
... , PHOENIX, Dec. 7 To standing cheers, ... (NNU) today unanimously endorsed the creation of the largest union ... and projected a major escalation in campaigns to expand union ... , "The promise of the future has arrived," said Karen ...
... Calif., Dec. 7 Patriot Scientific Corporation (OTC Bulletin ... its Board of Directors and will serve as chair ... 16 years of experience working in the software development ... and the delivery of consulting services for Cognizant Technology ...
... , LOS ANGELES, Dec. 7 Steeped in ... on Crystal Cruises, April 26 "Mind, Body and Spirit" ... the spiritual heritage of the region via personal meetings with ... meditation center, while guest health experts share insights on life ...
... , Department of Health Reminds At-Risk Pennsylvanians to ... federal Centers for Disease Control and Prevention, or CDC, ... flu vaccine to Pennsylvania to date, the state Department ... been distributed to 1,639 certified providers including pediatricians, family ...
Cached Medicine News:Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 2Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 3Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 4Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Unanimous Vote Creates Largest RN Union in U.S. History 2Health News:Patriot Scientific Corporation Announces New Director 2Health News:Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight' 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: